Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Intranasal (IN) Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the Pediatric Emergency Department

NCT04150757 is registered in ClinicalTrials.gov with Abigail Nixon as lead sponsor.

NCT NCT04150757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Intranasal (IN) Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the Pediatric Emergency Department
Lead sponsor
Abigail Nixon
Phase
Phase 3
Overall status
Terminated
Start date
December 19, 2019
Completion date
June 1, 2022
Enrollment
5 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

analgesia, intranasal ketamine, ketamine, sickle cell disease, vaso-occlusive crisis, vaso-occlusive pain episode in sickle cell disease